MA55807A - Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33 - Google Patents

Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33

Info

Publication number
MA55807A
MA55807A MA055807A MA55807A MA55807A MA 55807 A MA55807 A MA 55807A MA 055807 A MA055807 A MA 055807A MA 55807 A MA55807 A MA 55807A MA 55807 A MA55807 A MA 55807A
Authority
MA
Morocco
Prior art keywords
antagonist
administration
treating
methods
preventing asthma
Prior art date
Application number
MA055807A
Other languages
English (en)
Inventor
Raolat Abdulai
Nikhil Amin
Alex Boddy
Deborah Dukovic
Helene Goulaouic
Sivan Harel
Chih-Chi Hu
Andreas Jessel
Georgios Kalliolias
Marcella Ruddy
Ariel Teper
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA55807A publication Critical patent/MA55807A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055807A 2019-05-01 2020-04-30 Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33 MA55807A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841481P 2019-05-01 2019-05-01
US201962848248P 2019-05-15 2019-05-15
US201962898900P 2019-09-11 2019-09-11

Publications (1)

Publication Number Publication Date
MA55807A true MA55807A (fr) 2022-03-09

Family

ID=70802932

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055807A MA55807A (fr) 2019-05-01 2020-04-30 Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33

Country Status (15)

Country Link
US (1) US20210000949A1 (fr)
EP (1) EP3962515A1 (fr)
JP (1) JP2022530533A (fr)
KR (1) KR20220004708A (fr)
CN (1) CN113766931A (fr)
AU (1) AU2020266593A1 (fr)
BR (1) BR112021021195A2 (fr)
CA (1) CA3138306A1 (fr)
CO (1) CO2021015793A2 (fr)
IL (1) IL287275A (fr)
MA (1) MA55807A (fr)
MX (1) MX2021013427A (fr)
SG (1) SG11202111255YA (fr)
TW (1) TW202106334A (fr)
WO (1) WO2020223541A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500889TA (en) 2012-08-21 2015-03-30 Sanofi Sa Methods for treating or preventing asthma by administering an il-4r antagonist
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
WO2020191346A1 (fr) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
DK4244252T3 (da) 2021-08-27 2024-09-02 Medimmune Ltd Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof
EP4430211A1 (fr) * 2021-11-11 2024-09-18 Regeneron Pharmaceuticals, Inc. Traitement des maladies pulmonaires en fonction de la stratification du score de risque polygénique pour l'interleukine 33 (il-33)
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
SG11201500889TA (en) * 2012-08-21 2015-03-30 Sanofi Sa Methods for treating or preventing asthma by administering an il-4r antagonist
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CN106232140A (zh) * 2014-02-21 2016-12-14 赛诺菲生物技术公司 通过施用il‑4r拮抗剂治疗或预防哮喘的方法
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MA49131A (fr) * 2017-04-21 2020-03-25 Hoffmann La Roche Utilisation d'antagonistes de klk5 pour le traitement d'une maladie

Also Published As

Publication number Publication date
BR112021021195A2 (pt) 2022-03-03
CA3138306A1 (fr) 2020-11-05
SG11202111255YA (en) 2021-11-29
MX2021013427A (es) 2022-01-31
AU2020266593A1 (en) 2021-11-11
JP2022530533A (ja) 2022-06-29
CN113766931A (zh) 2021-12-07
WO2020223541A1 (fr) 2020-11-05
IL287275A (en) 2021-12-01
KR20220004708A (ko) 2022-01-11
EP3962515A1 (fr) 2022-03-09
TW202106334A (zh) 2021-02-16
US20210000949A1 (en) 2021-01-07
CO2021015793A2 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
MA55807A (fr) Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33
MA46098A (fr) Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MA46954A (fr) Méthodes de traitement d'états inflammatoires
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MA52624A (fr) Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
EA201892207A1 (ru) Индолкарбоксамидные соединения
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201990400A1 (ru) Соединения и композиции и их применение
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire